The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).
Ryan Bruce Corcoran
No relevant relationships to disclose
Gerald Steven Falchook
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
Jeffrey R. Infante
No relevant relationships to disclose
Omid Hamid
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Wells A. Messersmith
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Eunice Lee Kwak
Consultant or Advisory Role - Pfizer; Roche/Genentech (U)
Research Funding - GlaxoSmithKline
David P. Ryan
No relevant relationships to disclose
Razelle Kurzrock
Research Funding - GlaxoSmithKline
Adrienne A Brenner
No relevant relationships to disclose
Jennifer Luan
No relevant relationships to disclose
Peng Sun
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Alicia J Allred
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Shonda M Little
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Scott Kopetz
No relevant relationships to disclose
Alan Paul Venook
Research Funding - GlaxoSmithKline